NASDAQ:IMGN - ImmunoGen News Headlines

Sign in or create an account to add this stock to your watchlist.
$1.98 +0.05 (+2.59 %)
(As of 05/24/2019 04:00 PM ET)
Previous Close$1.93
Today's Range$1.88 - $1.99
52-Week Range$1.83 - $12.31
Volume89,185 shs
Average Volume3.69 million shs
Market Capitalization$296.07 million
P/E RatioN/A
Dividend YieldN/A
Beta2.12

Headlines

ImmunoGen (NASDAQ IMGN) News Headlines

Source:
DateHeadline
Biotech Stock Roundup: Label Expansion for CELGs Drugs, Setback for IMGN - Yahoo FinanceBiotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN - Yahoo Finance
finance.yahoo.com - May 22 at 4:30 PM
ImmunoGen: Assessing The Possibility Of A TurnaroundImmunoGen: Assessing The Possibility Of A Turnaround
seekingalpha.com - May 18 at 10:31 AM
Q3 2019 Earnings Estimate for ImmunoGen, Inc. (IMGN) Issued By William BlairQ3 2019 Earnings Estimate for ImmunoGen, Inc. (IMGN) Issued By William Blair
www.americanbankingnews.com - May 17 at 6:43 AM
ImmunoGen (IMGN) Price Target Cut to $4.00 by Analysts at HC WainwrightImmunoGen (IMGN) Price Target Cut to $4.00 by Analysts at HC Wainwright
www.americanbankingnews.com - May 16 at 4:58 PM
Why Immunogen Was Down by More than 30% on May 15Why Immunogen Was Down by More than 30% on May 15
finance.yahoo.com - May 16 at 4:23 PM
What Analysts Recommend for IMGN after Its Q1 ResultsWhat Analysts Recommend for IMGN after Its Q1 Results
finance.yahoo.com - May 16 at 4:23 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGN - Yahoo FinanceSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGN - Yahoo Finance
finance.yahoo.com - May 16 at 8:49 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGN - GlobeNewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGN - GlobeNewswire
www.globenewswire.com - May 15 at 9:32 PM
ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Ovarian CancerImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Ovarian Cancer
finance.yahoo.com - May 15 at 9:32 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGNSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGN
finance.yahoo.com - May 15 at 9:32 PM
Why The Childrens Place, Agilent Technologies, and Immunogen Slumped TodayWhy The Children's Place, Agilent Technologies, and Immunogen Slumped Today
www.fool.com - May 15 at 4:41 PM
ImmunoGen stock down more than 30% after FDA suggests conducting new Phase 3 trial for ovarian cancer drug - MarketWatchImmunoGen stock down more than 30% after FDA suggests conducting new Phase 3 trial for ovarian cancer drug - MarketWatch
www.marketwatch.com - May 15 at 4:26 PM
Guggenheim Downgrades ImmunoGen (IMGN) to NeutralGuggenheim Downgrades ImmunoGen (IMGN) to Neutral
www.americanbankingnews.com - May 15 at 12:25 PM
Catalyst Pharmaceuticals and Genetic Technologies among healthcare gainers; ImmunoGen leads the losers - Seeking AlphaCatalyst Pharmaceuticals and Genetic Technologies among healthcare gainers; ImmunoGen leads the losers - Seeking Alpha
seekingalpha.com - May 15 at 11:28 AM
ImmunoGen Provides Regulatory Update on Mirvetuximab Soravtansine Monotherapy in Ovarian CancerImmunoGen Provides Regulatory Update on Mirvetuximab Soravtansine Monotherapy in Ovarian Cancer
finance.yahoo.com - May 15 at 11:28 AM
ImmunoGen stock down more than 30% after FDA suggests conducting new Phase 3 trial for ovarian cancer drugImmunoGen stock down more than 30% after FDA suggests conducting new Phase 3 trial for ovarian cancer drug
finance.yahoo.com - May 15 at 11:28 AM
ImmunoGen Plunges as FDA Rejects Fast-Track Approval for Cancer DrugImmunoGen Plunges as FDA Rejects Fast-Track Approval for Cancer Drug
finance.yahoo.com - May 15 at 11:28 AM
ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1 - Yahoo FinanceImmunoGen (IMGN) Misses on Earnings & Revenues in Q1 - Yahoo Finance
finance.yahoo.com - May 8 at 11:23 AM
ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1 - NasdaqImmunoGen (IMGN) Misses on Earnings & Revenues in Q1 - Nasdaq
www.nasdaq.com - May 7 at 4:30 PM
$10.82 Million in Sales Expected for ImmunoGen, Inc. (IMGN) This Quarter$10.82 Million in Sales Expected for ImmunoGen, Inc. (IMGN) This Quarter
www.americanbankingnews.com - May 7 at 3:57 AM
ImmunoGen and Athenex among healthcare gainers; AAC Holdings and PetMed Express among losers - Seeking AlphaImmunoGen and Athenex among healthcare gainers; AAC Holdings and PetMed Express among losers - Seeking Alpha
seekingalpha.com - May 6 at 4:27 PM
ImmunoGen (IMGN) Rating Increased to Outperform at CowenImmunoGen (IMGN) Rating Increased to Outperform at Cowen
www.americanbankingnews.com - May 6 at 12:01 PM
ImmunoGen (IMGN) Upgraded at HC WainwrightImmunoGen (IMGN) Upgraded at HC Wainwright
www.americanbankingnews.com - May 6 at 11:05 AM
UPDATE: HC Wainwright Upgrades Immunogen Inc. (IMGN) to Buy - StreetInsider.comUPDATE: HC Wainwright Upgrades Immunogen Inc. (IMGN) to Buy - StreetInsider.com
www.streetinsider.com - May 6 at 10:33 AM
Is ImmunoGen, Inc. (IMGN) A Good Stock To Buy? - Yahoo FinanceIs ImmunoGen, Inc. (IMGN) A Good Stock To Buy? - Yahoo Finance
finance.yahoo.com - May 6 at 10:33 AM
ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1
finance.yahoo.com - May 6 at 10:32 AM
Zacks: Analysts Anticipate ImmunoGen, Inc. (IMGN) to Post -$0.28 EPSZacks: Analysts Anticipate ImmunoGen, Inc. (IMGN) to Post -$0.28 EPS
www.americanbankingnews.com - May 5 at 4:53 PM
ImmunoGen (IMGN) Reports Q1 Loss, Lags Revenue Estimates - Yahoo FinanceImmunoGen (IMGN) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
finance.yahoo.com - May 4 at 11:24 AM
Immunogen Inc. (IMGN) CEO Mark Enyedy on Q1 2019 Results - Earnings Call Transcript - Seeking AlphaImmunogen Inc. (IMGN) CEO Mark Enyedy on Q1 2019 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 4 at 11:24 AM
Edited Transcript of IMGN earnings conference call or presentation 3-May-19 12:00pm GMTEdited Transcript of IMGN earnings conference call or presentation 3-May-19 12:00pm GMT
finance.yahoo.com - May 4 at 11:24 AM
ImmunoGen (IMGN) Issues Quarterly  Earnings Results, Beats Expectations By $0.01 EPSImmunoGen (IMGN) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 3 at 8:38 PM
ImmunoGen Q1 top line off 57%; shares down 4% premarket - Seeking AlphaImmunoGen Q1 top line off 57%; shares down 4% premarket - Seeking Alpha
seekingalpha.com - May 3 at 4:23 PM
Immunogen Inc (IMGN) Q1 2019 Earnings Call Transcript - Yahoo FinanceImmunogen Inc (IMGN) Q1 2019 Earnings Call Transcript - Yahoo Finance
finance.yahoo.com - May 3 at 4:23 PM
Immunogen Inc (IMGN) Q1 2019 Earnings Call TranscriptImmunogen Inc (IMGN) Q1 2019 Earnings Call Transcript
www.fool.com - May 3 at 2:58 PM
Form 8-K IMMUNOGEN INC For: May 03 - StreetInsider.comForm 8-K IMMUNOGEN INC For: May 03 - StreetInsider.com
www.streetinsider.com - May 3 at 11:32 AM
ImmunoGen (IMGN) Reports Q1 Loss, Lags Revenue EstimatesImmunoGen (IMGN) Reports Q1 Loss, Lags Revenue Estimates
finance.yahoo.com - May 3 at 11:32 AM
ImmunoGen, Inc. (IMGN) to Post Q1 2020 Earnings of ($0.43) Per Share, William Blair ForecastsImmunoGen, Inc. (IMGN) to Post Q1 2020 Earnings of ($0.43) Per Share, William Blair Forecasts
www.americanbankingnews.com - May 3 at 10:37 AM
ImmunoGen, Inc. (NASDAQ:IMGN): What Are The Future Prospects? - Yahoo FinanceImmunoGen, Inc. (NASDAQ:IMGN): What Are The Future Prospects? - Yahoo Finance
finance.yahoo.com - May 2 at 4:24 PM
ImmunoGen, Inc. (NASDAQ:IMGN): What Are The Future Prospects?ImmunoGen, Inc. (NASDAQ:IMGN): What Are The Future Prospects?
finance.yahoo.com - May 2 at 4:24 PM
ImmunoGen, Inc. (IMGN) Receives Consensus Rating of "Hold" from BrokeragesImmunoGen, Inc. (IMGN) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - April 30 at 2:26 AM
Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for - Yahoo FinanceAnalysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
finance.yahoo.com - April 26 at 4:20 PM
Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - April 26 at 4:20 PM
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2019 Operating ResultsImmunoGen Announces Conference Call to Discuss Its First Quarter 2019 Operating Results
finance.yahoo.com - April 19 at 11:33 AM
ImmunoGen Stock Is in Trouble Going Into EarningsImmunoGen Stock Is in Trouble Going Into Earnings
investorplace.com - April 15 at 2:18 PM
Noteworthy Friday Option Activity: IMGN, SPWR, MMM - NasdaqNoteworthy Friday Option Activity: IMGN, SPWR, MMM - Nasdaq
www.nasdaq.com - April 12 at 6:08 PM
Heres Why ImmunoGen Tumbled 43% in March - Motley FoolHere's Why ImmunoGen Tumbled 43% in March - Motley Fool
www.fool.com - April 9 at 1:11 PM
Do Directors Own ImmunoGen, Inc. (NASDAQ:IMGN) Shares?Do Directors Own ImmunoGen, Inc. (NASDAQ:IMGN) Shares?
finance.yahoo.com - March 27 at 12:31 PM
ImmunoGen (IMGN) Down 50.2% Since Last Earnings Report: Can It Rebound?ImmunoGen (IMGN) Down 50.2% Since Last Earnings Report: Can It Rebound?
finance.yahoo.com - March 10 at 10:52 AM
Biotech Analysis Central Pharma News: Evokes Mishap, ImmunoGens Struggle, Eli Lillys Priority ReviewBiotech Analysis Central Pharma News: Evoke's Mishap, ImmunoGen's Struggle, Eli Lilly's Priority Review
seekingalpha.com - March 8 at 4:26 PM
Immunogen Ovarian Cancer Drug Fails in Phase III, Stock Sinks - Yahoo NewsImmunogen Ovarian Cancer Drug Fails in Phase III, Stock Sinks - Yahoo News
finance.yahoo.com - March 6 at 4:25 PM
This page was last updated on 5/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel